

# PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models



Terrence F. Meehan<sup>1</sup>, Nathalie Conte<sup>1</sup>, Theodore Goldstein<sup>2</sup>, Giorgio Inghirami<sup>3</sup>, Mark A. Murakami<sup>4</sup>, Sebastian Brabetz<sup>5,6</sup>, Zhiping Gu<sup>7</sup>, Jeffrey A. Wiser<sup>7</sup>, Patrick Dunn<sup>7</sup>, Dale A. Begley<sup>8</sup>, Debra M. Krupke<sup>8</sup>, Andrea Bertotti<sup>9</sup>, Alejandra Bruna<sup>10</sup>, Matthew H. Brush<sup>11</sup>, Annette T. Byrne<sup>12</sup>, Carlos Caldas<sup>10</sup>, Amanda L. Christie<sup>4</sup>, Dominic A. Clark<sup>1</sup>, Heidi Dowst<sup>13</sup>, Jonathan R. Dry<sup>14</sup>, James H. Doroshow<sup>15</sup>, Olivier Duchamp<sup>16</sup>, Yvonne A. Evrard<sup>17</sup>, Stephane Ferretti<sup>18</sup>, Kristopher K. Frese<sup>19</sup>, Neal C. Goodwin<sup>20</sup>, Danielle Greenawalt<sup>21</sup>, Melissa A. Haendel<sup>11</sup>, Els Hermans<sup>22</sup>, Peter J. Houghton<sup>23</sup>, Jos Jonkers<sup>24</sup>, Kristel Kemper<sup>24</sup>, Tin O. Khor<sup>25</sup>, Michael T. Lewis<sup>26</sup>, K.C. Kent Lloyd<sup>27</sup>, Jeremy Mason<sup>1</sup>, Enzo Medico<sup>9</sup>, Steven B. Neuhauser<sup>8</sup>, James M. Olson<sup>28</sup>, Daniel S. Peeper<sup>24</sup>, Oscar M. Rueda<sup>10</sup>, Je Kyung Seong<sup>29</sup>, Livio Trusolino<sup>9</sup>, Emilie Vinolo<sup>30</sup>, Robert J. Wechsler-Reya<sup>31</sup>, David M. Weinstock<sup>4</sup>, Alana Welm<sup>32</sup>, S. John Weroha<sup>33</sup>, Frédéric Amant<sup>24,34</sup>, Stefan M. Pfister<sup>5,6,35</sup>, Marcel Kool<sup>5,6</sup>, Helen Parkinson<sup>1</sup>, Atul J. Butte<sup>2</sup>, and Carol J. Bult<sup>8</sup>

## Abstract

Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug response and resistance, and tailoring chemotherapeutic approaches for individual patients. The lack of robust standards for reporting on PDX models has hampered the ability of researchers to find relevant PDX models and associated data. Here we present the PDX models minimal information standard (PDX-MI) for reporting on the generation, quality assurance, and use of PDX models.

PDX-MI defines the minimal information for describing the clinical attributes of a patient's tumor, the processes of implantation and passaging of tumors in a host mouse strain, quality assurance methods, and the use of PDX models in cancer research. Adherence to PDX-MI standards will facilitate accurate search results for oncology models and their associated data across distributed repository databases and promote reproducibility in research studies using these models. *Cancer Res*; 77(21); e62–66. ©2017 AACR. [+](#)

<sup>1</sup>European Molecular Biology Laboratory-European Bioinformatics Institute, Hinxton, United Kingdom. <sup>2</sup>Institute for Computational Health Sciences, University of California, San Francisco, California. <sup>3</sup>Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York. <sup>4</sup>Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. <sup>5</sup>Hopp-Children's Cancer Center at the NCT Heidelberg (KITZ), Heidelberg, Germany. <sup>6</sup>Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany. <sup>7</sup>Northrop Grumman Information Systems Health IT, Rockville, Maryland. <sup>8</sup>The Jackson Laboratory, Bar Harbor, Maine. <sup>9</sup>Candiolo Cancer Institute, FPO-IRCC, Department of Oncology, University of Torino, Torino, Italy. <sup>10</sup>Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge, United Kingdom. <sup>11</sup>Department of Medical Informatics and Clinical Epidemiology and OHSU Library, Oregon Health and Science University, Portland, Oregon. <sup>12</sup>Royal College of Surgeons in Ireland, Ireland. <sup>13</sup>Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas. <sup>14</sup>Oncology Innovative Medicines and Early Development, AstraZeneca R&D Boston, Waltham, Massachusetts. <sup>15</sup>Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. <sup>16</sup>Oncodesign Biotechnology and IMODI Consortium, France. <sup>17</sup>Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland. <sup>18</sup>Oncology Disease Area, Novartis Institutes for Biomedical Research, Switzerland. <sup>19</sup>Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom. <sup>20</sup>Champions Oncology, Baltimore, Maryland. <sup>21</sup>Translational Bioinformatics Bristol-Myers Squibb, Pennington, New Jersey. <sup>22</sup>Katholieke Universiteit Leuven, Leuven, Belgium. <sup>23</sup>Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas. <sup>24</sup>The Netherlands Cancer

Institute, Amsterdam, the Netherlands. <sup>25</sup>Institute for Applied Cancer Science, Center for Co-Clinical Trial, The University of Texas MD Anderson Cancer Center, Houston, Texas. <sup>26</sup>The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and Radiology, Baylor College of Medicine, Houston, Texas. <sup>27</sup>Department of Surgery, School of Medicine, and Mouse Biology Program, University of California Davis, Davis, California. <sup>28</sup>Fred Hutchinson Cancer Research Center, Seattle Children's Hospital, Seattle, Washington. <sup>29</sup>Research Institute for Veterinary Science and Korea Mouse Phenotyping Center, Seoul, Republic of Korea. <sup>30</sup>Seeding Science SAS, Paris, France. <sup>31</sup>Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, La Jolla, California. <sup>32</sup>Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. <sup>33</sup>Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota. <sup>34</sup>University of Leuven, Leuven, Belgium. <sup>35</sup>Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.

**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

T.F. Meehan and N. Conte contributed equally to the article.

**Corresponding Author:** Terrence Meehan, European Molecular Biology Laboratory-European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, United Kingdom. Phone: 44-0-1223-49-2591; Fax: 44-0-1223-49-4468; E-mail: [tmeehan@ebi.ac.uk](mailto:tmeehan@ebi.ac.uk)

**doi:** 10.1158/0008-5472.CAN-17-0582

©2017 American Association for Cancer Research.

## Introduction

Patient-derived tumor xenograft (PDX) models are created by implanting tumor cells or fragments from patients with cancer into a transplant-compliant mouse host (Supplementary Fig. S1; refs. 1, 2). Human tumors that engraft successfully in host mice are subsequently fragmented and passaged multiple times to generate large cohorts of tumor-bearing mice. PDX models accurately reflect the patient's tumor properties, creating a powerful platform to study the molecular mechanisms of tumor growth and drug resistance as well as serving as patient "avatars" for predicting response to anticancer therapeutic compounds (3–5). The host strains for PDX model development are typically severely immunodeficient; however, "humanized" immune system mice engrafted with human immune cells are increasingly being used in xenograft studies to explore *in vivo* interactions between the immune system and cancer (6, 7).

Although many academic and commercial sources of PDX models have emerged in recent years, the size of the resources and the processes for creating and characterizing PDX models is quite variable. Crucial information about tumors, host strains, transplant, and quality assurance processes are inconsistently presented in both the scientific literature and in database resources, limiting the ability of researchers to find relevant models and associated data. A standardized data exchange format is needed to foster the ability of researchers to identify appropriate PDX models and to share information about them. As developers of NCI-funded informatics resources, we obtained the internal standards developed by four independent PDX model resources [the EurOPDX consortium (5), the IMODI consortium (France), the Patient-Derived Models Repository at NCI-Frederick, and The Jackson Laboratory PDX Resource (8)]. After comparing standards in use across these resources, we generated a draft PDX-minimal information standard (PDX-MI) that was reviewed and modified by the authors of this report. We propose that the standards described here serve as the starting point for community-wide adoption.

## The PDX-MI Standard

The PDX-MI consists of four modules that reflect the process of generating, validating, and using a PDX model: clinical, model creation, model quality assurance, model study, and an additional associated metadata category (Table 1). Within each module, we define "essential" attributes that are required for accurate description and reporting on PDX models and "desirable" attributes that are frequently recorded by PDX producers and should be available.

The clinical module is divided into two submodules: "clinical/patient" and "clinical/tumor." "Clinical/patient" requires information about the patient from which the engrafted tumor originates, including age, sex, ethnicity, and disease diagnosis. To reduce the possibility of patient identification, PDX-MI recommends grouping ages into 5-year groups, although more granular groupings may be used in cases such as pediatric tumors if approved by a contributor's Institutional Review Board. Reporting on patient consent is considered essential as well. Some attributes of patient treatment history are listed as "desirable" as they can impact the characteristics of resulting PDX models but may be challenging to provide due to patient privacy or data inaccessibility. The "clinical/tumor" submodule reports on information about the originating tumor from which the PDX model is derived

and includes tumor classification, anatomic location, and tumor histopathology. The presence or absence of specific diagnostic markers is listed as "essential" for tumor types where testing for such marker(s) is considered the clinical standard of care (e.g., FLT3 genotype in acute myelogenous leukemia). In addition, patient viral infection status has implications for disease biology as well as occupational safety and is included as a desirable field.

The model creation module of PDX-MI captures critical attributes in the creation of a PDX model. Host strain is reported using official strain nomenclature (<http://www.informatics.jax.org/mgi/home/nomen/index.shtml>) as well as strain source and any modifications that "humanize" the host strain through engraftment of human immune-progenitor cells (6). Initial engraftment of the tumor describing processing of the tumor (solid or cell suspension) and the anatomic site of implantation (subcutaneous or orthotopic) is represented. Other model generation characteristics such as engraftment rates and therapeutic response data are considered desirable. A "subline" field indicates when a PDX model is derived from an existing model that has changed characteristics (e.g., loss/gain of a biomarker, change in therapy response).

The model quality assurance module captures information about tissue provenance and fidelity of the passaged tumor with respect to key characteristics of the patient tumor. Validation is required to confirm the PDX tumor is of the appropriate patient and not of murine origin nor consisting primarily of Epstein-Barr virus human B lymphocytic cells as both are frequently observed in PDX model creation (9). Other "desirable" quality assurance methods vary with tumor types and can include histopathology, assessment of human cancer biomarkers by IHC, *in situ* hybridization, and assessment of gene mutations and rearrangements, DNA methylation, or gene expression profiling. Some producers evaluate how well a PDX model recapitulates the originating tumor's response by measuring PDX tumor growth response to standard-of-care treatment and this is included as a desirable attribute. Additional desirable information includes DNA profiling of serial passages to corroborate lineage fidelity and animal health status from standard health surveillance programs. The current PDX-MI requires evidence of quality assurance but does not require every possible technique be performed as methods vary across resources.

### Model study and other associated data

Tumors from PDX often undergo comprehensive genomic characterization and/or treatment in controlled dosing studies to define therapeutic response and resistance. PDX-MI includes "desirable" fields in the reporting of these studies that supplement existing guidelines for reporting on *in vivo* biomedical research (10). Additional optional metadata are accession IDs from data archives and citation IDs (including digital object identifiers) for publications describing the PDX model(s).

## Challenges of Representing Data from PDX Models

### Diversity of cancer subtypes

PDX models present unique challenges due to the specific approaches needed for the diversity of cancer subtypes. One challenge is that a subset of PDX models will require reporting on diagnostic biomarkers. For example, in breast cancer, testing for certain pathologic markers (estrogen receptor, progesterone receptor, and

**Table 1.** The PDX-MI consists of four modules that reflect the process of generating and validating a PDX model: clinical, model creation, model quality assurance, and model study/associated metadata

Module	Field	Recommendation	Example entry or choice	
Clinical/patient	Submitter patient ID	Essential	PAT-123	
	Gender	Essential	Female	
	Age	Essential	30–35 (binned in 5-year age groups)	
	Diagnosis	Essential	Invasive breast cancer	
	Consent to share data	Essential	Yes/no/available to academic centers only	
	Ethnicity/race	Desirable	Caucasian	
	Current treatment drug	Desirable	Everolimus; CHEMBL83	
	Current treatment protocol (dose; details)	Desirable	Afinitor; 10 mg/day	
	Prior treatment protocol	Desirable	Surgery and nolvadex; 40 mg/day	
	Response to prior treatment	Desirable	Progressive disease (RECIST1.1)	
	Virology status	Desirable	HIV–/HBV–/HCV+/HTLV–/EBV+	
	Clinical/tumor	Submitter tumor ID	Essential	TUM-123
		Primary tumor tissue of origin	Essential	Breast
Primary, metastasis, recurrence		Essential	Metastasis	
Specimen tumor tissue		Essential	Liver	
Tissue histology		Essential	Invasive ductal carcinoma	
Tumor grade; classification		Essential	Grade 3; Elston	
Disease stage; classification		Essential	T3N2M1; TNM or nonapplicable (example blood cancer)	
Specific markers (diagnostic linked); platform		Essential	ER+, PR+, HER2+; IHC	
Is tumor from untreated patient?		Essential	Yes/no	
Original tumor sample type		Desirable	Biopsy, surgical sample, ascites fluid, blood, etc.	
Tumor from an existing PDX model? ID? Why sub-line?		Desirable	Yes, PDX#123, lost cisplatin resistance	
Model creation	Submitter PDX ID	Essential	PDX#123	
	Mouse strain (and source)	Essential	NOD.Cg-Prkdc <sup>scid</sup> Il2rg <sup>tm1Wjl</sup> /SzJ, The Jackson Laboratory	
	Strain immune system humanized?	Essential	Yes/no	
	Type of humanization	Essential	CD34 <sup>+</sup> hematopoietic stem cell-engrafted/PBMC/thymus/thymus-fetal liver/iPSC/other	
	Tumor preparation	Essential	Tumor solid, cell suspension, asite	
	Injection type and site	Essential	Subcutaneous; right flank	
	Mouse treatment for engraftment	Desirable	Estrogen treatment	
	Engraftment rate	Desirable	80%	
	Engraftment time	Desirable	8 weeks	
Model quality assurance	Tumor characterization technology	Essential	Histology and IHC	
	Tumor confirmed not to be of mouse/EBV origin	Essential	Yes/no; negative for murine CD45	
	Response to standard of care (pharmacologic positive control)	Desirable	Not assessed/assessed—complete response, partial response, stable disease, progressive disease	
	Animal health status	Desirable	SPF/SOPF, <i>C. Bovis</i> , and <i>Pneumocystis</i> negative/positive	
	Passage QA performed	Essential	Passage P4	
Model study	Treatment, passage	Desirable	Pertuzumab in combination with trastuzumab; CHEMBL2007641 and CHEMBL1743082; passage P4	
	Treatment protocol (dose; details)	Desirable	Trastuzumab (30 mg/kg loading dose, 15 mg/kg weekly); pertuzumab (30 mg/kg loading dose, 15 mg/kg weekly)	
	Treatment response	Desirable	Complete response, partial response, stable disease, progressive disease	
	Tumor OMICS: sample id; sample site; purity (mouse vs. human); technology; passage	Desirable	TUMpdx-123; subcutaneous; 90% human; exome sequencing; passage P5	
	Development of metastases in strain (Y/N, site); passage	Desirable	Yes; liver; passage P6	
	Lag time/doubling time of tumor	Desirable	48 hours	
	Associated metadata	PDX model availability?	Desirable	Yes/no; frozen tumor; live mouse
Governance restriction for distribution		Desirable	Available to academic centers only	
ID for associated publication, image, archived data (URL, PMID, DOI)		Desirable	www.ebi.ac.uk/ena/data/view/PRJEB11482; PMID:28025748; DOI: 10.1186/s13058-015-0523-1	

NOTE: The "field" column describes each module attribute; the "recommendation" column defines whether the attribute is essential or desirable. All essential attributes must be submitted to provide an accurate description and reporting of PDX models; desirable attributes should be submitted if available. Finally the "example entry" gives an example(s) of each attribute.

Abbreviations: EBV, Epstein-Barr virus; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2.

human epidermal growth factor 2) is considered the clinical standard of care for prognostic and predictive purposes and should therefore be considered essential for PDX-MI. Another challenge is that tumor grades and disease stages captured in the "clinical module," which drive patient diagnosis and treatment, may be derived from scoring systems with diagnostic and geographic variation (11). PDX-MI will be flexible and allow users to report the system used clinically rather than enforce a particular one.

### Terminology and vocabularies

PDX resources employ a combination of custom and community-developed vocabularies. This presents challenges in data integration, as it takes expert knowledge to map the divergent systems. For example, cancer diagnoses are represented within different PDX resources by terms from the NCI-Thesaurus (12), SNO-MED CT (13), MeSH (14), and the Disease Ontology (15). Free text descriptions are used for many PDX model attributes and a mix of generic, commercial, and chemical labels are used for drugs. Ontology resources and community model organism databases have been developing tools to semiautomate mapping of standards that produce unified indices to facilitate data query and discovery. Rather than impose a limited set of terms to describe a given minimal information attribute, PDX-MI will allow the reporting of a resource's internal standards. We will ensure the quality of standard mappings by facilitating feedback between the PDX producers and the developers of ontology tools.

### Implementation and Future Directions

The current version of PDX-MI describes the minimal information needed to report on a PDX models to facilitate data integration and resource sharing. The authors of this report hope PDX-MI will serve as a guide for authors and journal editors in promoting rigorous yet attainable publication standards and as a template for managers of public molecular archives in the capturing of critical metadata required for submission of PDX model data. PDX-MI standards will also be implemented in an online resource being jointly developed by EMBL-EBI and the Jackson Laboratory called PDX Finder, [www.pdxfinder.org](http://www.pdxfinder.org) (see Supplementary Video S1). This resource currently in the prototype phase will provide a comprehensive global catalog of PDX models available for researchers and their associated data across distributed repositories when formally launched at the end of 2017. PDX-MI will be used to validate data submissions from producers of PDX models and from data curated from the literature. PDX-MI will also inform scoring algorithms being developed in the NCI Oncology Models Forum to assess how well PDX models recapitulate hallmarks of human cancers.

Future versions of PDX-MI will capture additional details as procedures become more standardized. Input from clinical and translational professional societies will inform evolving requirements for diagnostic markers on a disease-specific basis. Given the recent success of immune checkpoint inhibitors in the treatment of cancer, improving "humanized immune system" PDX models is an area of intense research and PDX-MI will evolve to represent this. Other aspects of PDX models that are rapidly changing include improved surgical techniques and quality assurance methods. As we develop resources to capture and disseminate data related to PDX models, we will continue to improve and version PDX-MI to reflect the state of the art in

the field. A web-based form to allow feedback from the community about the standard described here can be accessed at the Mouse Tumor Biology database website (<http://tumor.informatics.jax.org>). As has been demonstrated across multiple disciplines, a minimal standard adopted by a research community accelerates the rate of scientific discovery while reducing unnecessary duplication.

### Disclosure of Potential Conflicts of Interest

S. Ferretti is a laboratory head at Novartis. M.T. Lewis is a manager and limited partner at StemMed Holdings. E. Vinolo is a consultant/advisory board member for EurOPDX Consortium and XenTech. D.M. Weinstock reports receiving a commercial research grant from Novartis, AstraZeneca, Abbvie, Aileron, Roche, and Novartis, has ownership interest (including patents) in Travera, and has provided expert testimony for Monsanto. S.J. Werooha reports receiving a commercial research grant from Novartis, Genentech, and Tesaro and has ownership interest (including patents) in Mayo Clinic Ventures. A.J. Butte is a cofounder and scientific advisor at Personalis, Inc. and NuMedii, Inc., reports receiving a commercial research grant from Progenity, Inc., and has ownership interest (including patents) in NuMedii, Inc. No potential conflicts of interest were disclosed by the other authors.

### Authors' Contributions

**Conception and design:** T.F. Meehan, T. Goldstein, G. Inghirami, S. Brabetz, Z. Gu, D.A. Begley, D.M. Krupke, C. Caldas, D.A. Clark, J.R. Dry, Y.A. Evrard, N.C. Goodwin, D. Greenawalt, E. Hermans, P.J. Houghton, T.O. Khor, J.M. Olson, J.K. Seong, R.J. Wechsler-Reya, S.J. Werooha, A.J. Butte, H. Parkinson, C.J. Bult

**Development of methodology:** T.F. Meehan, T. Goldstein, J.A. Wiser, P. Dunn, D.A. Begley, D.M. Krupke, J.H. Doroshow, N.C. Goodwin, D. Greenawalt, M.A. Haendel, E. Hermans, P.J. Houghton, T.O. Khor, M.T. Lewis, J.M. Olson, L. Trusolino, C.J. Bult

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** T.F. Meehan, N. Conte, D.A. Begley, Y.A. Evrard, E. Hermans, J. Jonkers, J.M. Olson, L. Trusolino, E. Vinolo, F. Amant, C.J. Bult

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** N. Conte, T. Goldstein, G. Inghirami, D.A. Begley, D.M. Krupke, H. Dowst, J.H. Doroshow, J.M. Olson, O.M. Rueda, J.K. Seong

**Writing, review, and/or revision of the manuscript:** T.F. Meehan, N. Conte, T. Goldstein, G. Inghirami, M.A. Murakami, S. Brabetz, Z. Gu, P. Dunn, D.A. Begley, D.M. Krupke, A. Bertotti, A. Bruna, M.H. Brush, A.T. Byrne, C. Caldas, A.L. Christie, D.A. Clark, J.R. Dry, O. Duchamp, Y.A. Evrard, S. Ferretti, K.K. Frese, N.C. Goodwin, D. Greenawalt, M.A. Haendel, E. Hermans, P.J. Houghton, K. Kemper, M.T. Lewis, K.C.K. Lloyd, E. Medico, S.B. Neuhauser, D.S. Peeper, J.K. Seong, E. Vinolo, R.J. Wechsler-Reya, D.M. Weinstock, A. Welm, S.J. Werooha, F. Amant, S.M. Pfister, M. Kool, A.J. Butte, C.J. Bult

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** T.F. Meehan, N. Conte, M.A. Murakami, P. Dunn, D.A. Begley, D.M. Krupke, C. Caldas, O. Duchamp, K.C.K. Lloyd, J. Mason, S.B. Neuhauser, S.M. Pfister, C.J. Bult

**Study supervision:** N. Conte, T.O. Khor, H. Parkinson

**Other (management of industry stakeholders):** D.A. Clark

### Grant Support

This project has been funded in whole or in part with federal funds from the National Cancer Institute, NIH: R01CA089713D (to C.J. Bult), P30CA034196 (to C.J. Bult), U24CA204781 (to H. Parkinson), U24CA195858 (to A.J. Butte), contract no. HHSN26120080001E (to J.H. Doroshow, Y.A. Evrard), R24OD011883 (M.H. Brush, M.A. Haendel), the Leukemia & Lymphoma Society SCOR grant (2015, 2016; to G. Inghirami), and the Science Foundation Ireland grants 13/CDA/2183 and 15/TIDA/2963 and the Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT Grant CCRC13GAL (A.T. Byrne). G. Inghirami, A. Bertotti, A. Bruna, A.T. Byrne, C. Caldas, E. Hermans, J. Jonkers, K. Kemper, E. Medico, D.S. Peeper, O.M. Rueda, L. Trusolino, and F. Amant are members of the EurOPDX Consortium.

Received February 27, 2017; revised April 20, 2017; accepted August 25, 2017; published online November 1, 2017.

## References

1. Uthamanthil R, Tinkey P, De Stanchina E. Patient derived tumor xenograft models promise potential and practice. London: Academic Press; 2017.
2. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. *Cancer Discov* 2014;4:998–1013.
3. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. *Nat Rev Clin Oncol* 2012;9:338–50.
4. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. *Clin Cancer Res* 2012;18:5160–2.
5. Byrne AT, Alf rez DG, Amant F, Annibaldi D, Arribas J, Biankin AV, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. *Nat Rev Cancer* 2017;17:254–68.
6. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. *Nat Rev Immunol* 2012;12:786–98.
7. Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL, Greiner D. Human cancer growth and therapy in immunodeficient mouse models. *Cold Spring Harb Protoc* 2014;2014:694–708.
8. Bult CJ, Krupke DM, Begley DA, Richardson JE, Neuhauser SB, Sundberg JP, et al. Mouse Tumor Biology (MTB): a database of mouse models for human cancer. *Nucleic Acids Res* 2015;43:D1818–24.
9. Bondarenko G, Ugolkov A, Rohan S, Kulesza P, Dubrovskiy O, Gursel D, et al. Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. *Neoplasia* 2015;17:735–41.
10. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *PLoS Biol* 2010;8:e1000412.
11. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 2010;17:1471–4.
12. Sioutos N, de Coronado S, Haber MW, Hartel FW, Shaiu WL, Wright LW. NCI Thesaurus: A semantic model integrating cancer-related clinical and molecular information. *J Biomed Inform* 2007;40:30–43.
13. National Institute of Health-National Library of Medicine. SNOMED Clinical Terms® (SNOMED CT®) [Internet]. Available from: [http://www.nlm.nih.gov/research/umls/Snomed/snomed\\_main.html](http://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html)
14. National Library of Medicine. MeSH (Medical Subject Headings): is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed [Internet]. Available from: <http://www.ncbi.nlm.nih.gov/mesh>
15. Kibbe WA, Arze C, Felix V, Mitraka E, Bolton E, Fu G, et al. Disease Ontology 2015 update: an expanded and updated database of Human diseases for linking biomedical knowledge through disease data. *Nucleic Acids Res* 2015;43:D1071–8.